Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.52 |
| ▸ | HPRT1 | P00492 | 5/20 | 0.48 |
| ▸ | PNP | P00491 | 5/20 | 0.48 |
| ▸ | TK1 | P04183 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19569930 | 0.88 | XDH (0.55) | XDHHPRT1PNPTK1MEN1 | |
| SCHEMBL24222060 | 0.84 | XDH (0.35) | XDHHPRT1PNPTK1MEN1 | |
| SCHEMBL21137208 | 0.83 | XDH (0.55) | XDHHPRT1PNPTK1MEN1 | |
| SCHEMBL48090 | 0.79 | XDH (0.51) | XDHHPRT1PNPTK1MEN1 | |
| SCHEMBL29138701 | 0.78 | XDH (0.48) | XDHHPRT1PNPTK1MEN1 | |
| SCHEMBL7209513 | 0.77 | MEN1 (0.49) | XDHHPRT1PNPTK1MEN1 | |
| 9-Methylguanine SCHEMBL22884 | 0.76 | XDH (0.58) | XDHHPRT1PNPTK1MEN1 | |
| SCHEMBL986800 | 0.76 | XDH (0.60) | XDHHPRT1PNPTK1MEN1 | |
| SCHEMBL20442302 | 0.76 | XDH (0.55) | XDHHPRT1PNPTK1MEN1 | |
| 9-Methylguanine SCHEMBL27339404 | 0.75 | XDH (0.57) | XDHHPRT1PNPTK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | XDH 1435/4885HPRT1 248/4885PNP 174/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | XDH 592/4885HPRT1 139/4885PNP 138/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | XDH 592/4885HPRT1 139/4885PNP 138/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | XDH 592/4885HPRT1 139/4885PNP 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.